ValueSeptember 28, 2026

Buy the Dip Monday: The $186 Semiconductor Stock Wall Street Says Will Hit $1,855

Top 5 Pixie Picks

This Week's Setup

The screen is pricing semiconductor equipment at 5.3× earnings with a 15.4% FCF yield while analysts project ten-times upside from the current price.

Regional banks are trading below book value with 8–9% FCF yields and three to four insider filings in the last ten days.

Education technology and natural gas producers are sitting in deep dip zones with double-digit revenue growth and Wall Street price targets 35–40% above today's levels.

Quick Scan

#	Ticker	One-line thesis
1	KLAC	Semiconductor equipment with 19% earnings yield, 895% analyst upside
2	AMAL	Regional bank at 14× earnings, 9.5% FCF yield, insider filings
3	LRN	EdTech with 11% FCF yield, 18% revenue growth, 49% drawdown
4	ACAD	CNS pharma at 10× earnings, 92% gross margin, 31% drawdown
5	EQT	Natural gas at 10× earnings, 60% revenue growth, 38% upside
6	NEM	Gold producer with 30% ROIC, 6% FCF yield, insider activity
7	BANC	California bank under book, 8.5% FCF yield, 27% upside
8	VSNT	Media at 6× earnings, 40% FCF yield, 43% drawdown

The 8 Names

1. KLA Corporation (KLAC)

P/E: 5.28 | Earnings yield: 18.9% | 52w drawdown: -39.4%

The company is pricing at 5.3× earnings with a 15.4% FCF yield and 66% return on invested capital while delivering 24% year-over-year revenue growth and 61% gross margins. Analysts see the stock rising 895% from $186 to $1,855, a ten-bagger projection on what the market is treating as a value trap.

The current EV/EBITDA ratio sits at 43.5×, a premium that contradicts the single-digit P/E and suggests the market is discounting a severe earnings decline or restructuring event. The debt-to-equity ratio of 1.31 and 2.6% short interest flag modest concern, but neither explains the analyst target disconnect.

CEO Richard Wallace filed a Form 4 on September 16; the filing shows activity but no net share accumulation in the dataset. Next earnings arrive October 28 with consensus at $1.18 per share on $4.0 billion revenue.

2. Amalgamated Financial Corp. (AMAL)

P/E: 13.76 | Earnings yield: 7.3% | 52w drawdown: -8.3%

The regional bank trades at 13.8× earnings with a 9.5% FCF yield, a 1.3% dividend yield, and 4.4% revenue growth; the yield spread over the normalized 10-year rate is 520 basis points. Debt-to-equity sits at 0.10, a balance sheet posture that gives management room to absorb rate volatility or loan-loss provisions without capital raises.

Three Form 4 filings landed between September 10 and September 11 from Tenner, Romney, and Brown; all three were net sellers, moving 1,360 shares out in aggregate. The insider sell percentage is 100% over the last six months, a unanimous signal that internal holders are reducing exposure into the current price.

Analysts peg fair value at $46, 2.8% below the current $47.33 price, which means the street sees zero upside from here. The moderate drawdown and low short interest of 4.8% suggest the market is waiting for a catalyst before repricing the name higher.

3. Stride, Inc. (LRN)

P/E: 12.38 | Earnings yield: 8.1% | 52w drawdown: -49.0%

The education technology provider is sitting in a deep dip zone with 17.9% year-over-year revenue growth, an 11.1% FCF yield, and a 39.2% gross margin. The company generated a 25.5% return on invested capital, and analysts see 43.5% upside to $113.50 from the current $79.11.

Three insiders filed Form 4s in the last 20 days: Shepherd on September 8 and September 22, and Goldthwaite on September 18. The filings show activity but no significant net share accumulation in the six-month window; the insider dataset flags no aggregate buying signal.

Short interest is 16.4% of float, the highest bearish positioning on this screen and a signal that hedge funds are betting the revenue growth stalls or the valuation compresses further. The stock trends flat over the last twelve months, which means the drawdown has not yet sparked a reversal.

4. ACADIA Pharmaceuticals Inc. (ACAD)

P/E: 9.62 | Earnings yield: 10.4% | 52w drawdown: -31.3%

The CNS-focused pharma trades at 9.6× earnings with a 92% gross margin, 19.4% return on invested capital, and 11.9% revenue growth. The setup here is a company generating actual profit with a 2.9% FCF yield and a debt-to-equity ratio of 0.04, a clean balance sheet in a sector that often burns cash.

The EV/EBITDA ratio of 31.1× is elevated relative to the single-digit P/E, a spread that suggests the market expects near-term EBITDA compression or is discounting pipeline risk. Analysts see 48.8% upside to $31.65, but the stock trades flat over the trailing year despite the deep drawdown.

Recent news mentions a 29% drop tied to remifanserin data from the RADIANT trial; Deutsche Bank commentary and analyst price-target cuts followed the readout. Short interest is 9.0% of float, a moderate bet that the sell-off has further to run or that pipeline catalysts disappoint.

5. EQT Corporation (EQT)

P/E: 9.65 | Earnings yield: 10.4% | 52w drawdown: -25.5%

The natural gas producer trades at 9.7× earnings with an 8.9% FCF yield, 60% year-over-year revenue growth, and a 46% gross margin. The company sits on an EV/EBITDA ratio of 5.7× and a debt-to-equity ratio of 0.25, a capital structure that supports distribution or reinvestment without refinancing pressure.

Recent news highlights a record lateral well length and an Appalachia/Haynesville acquisition by WhiteHawk; EQT set a record well length, a technical milestone that lowers drilling costs per unit of gas recovered. Analysts see 37.7% upside to $70.04 from the current $50.88.

Revenue growth of 60% is impressive but flags integration or operational risk if the expansion came through acquisition rather than organic production gains. The stock trends flat over the last twelve months, and short interest is only 3.4%, which means the market is not yet convinced the drawdown is an entry point.

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Value stocks.

6. Newmont Corporation (NEM)

P/E: 15.69 | Earnings yield: 6.4% | 52w drawdown: -10.6%

The gold producer delivers a 30% return on invested capital with a 5.7% FCF yield, 21.3% revenue growth, and a 53% gross margin. The company maintains a 0.9% dividend yield and a debt-to-equity ratio of 0.16, a balance sheet that supports shareholder returns without leverage stress.

Three insiders filed Form 4s on September 3 (Toth, Viljoen, Beaven); all three were net sellers, moving 18,394 shares out over the six-month period. The insider sell percentage is 100%, a unanimous signal that management and directors are reducing exposure at current prices.

Analysts see only 18.1% upside to $142.82, the lowest projected gain on this screen and a sign that the street views the current $120.96 price as close to fair value. Short interest is 1.8%, indicating minimal bearish conviction.

7. Banc of California, Inc. (BANC)

P/E: 13.77 | Earnings yield: 7.3% | 52w drawdown: -18.4%

The California bank trades at 0.90× book value with an 8.5% FCF yield, a 2.7% dividend yield, and 11.9% revenue growth. The yield spread over the normalized 10-year rate is 208 basis points, and the debt-to-equity ratio of 1.02 is standard for a regional bank operating model.

Three Form 4 filings arrived between September 11 and September 22 from Dotan, Richardson, and Zandpour; the six-month dataset shows 305.9 million net shares sold, all from insider dispositions with zero offsetting buys. The stock trends flat over the last year, and analysts see 26.7% upside to $22.68.

Short interest is 7.5% of float, a moderate bet that the bank faces credit losses, deposit outflows, or margin compression as rate policy shifts. Recent news mentions short-term pain and risk already priced in; the market is waiting for proof that the current valuation reflects bottom-of-cycle earnings.

8. Versant Media (MS NOW) (VSNT)

P/E: 6.04 | Earnings yield: 16.6% | 52w drawdown: -43.4%

The media company trades at 6.0× earnings with a 40% FCF yield, a 4.5% dividend yield, and a 56% gross margin. The normalized 10-year P/E is 3.5×, suggesting the current multiple is already above the long-run average despite the deep drawdown.

Revenue declined 5.3% year-over-year, and next quarter's consensus calls for a $0.04 loss on $1.6 billion revenue. The stock trends flat over the trailing twelve months, and the EV/EBITDA ratio of 3.0× flags a market expectation that EBITDA contracts further or that the business faces secular headwinds.

Citigroup initiated coverage at Buy with a $41 target, and Barron's listed the name among the cheapest stocks in the S&P 500, framing the question as bargain or trap. Analysts project 33.5% upside from $33.40, but the political risk and revenue decline mean the thesis depends on a turnaround that has not yet started.

What to Watch

• October 20–28 earnings window: EQT reports October 20, AMAL and NEM on October 22, LRN on October 27, KLAC on October 28. Four of the top five names on this screen release results within eight days, a concentrated catalyst window that will reset price targets and test the deep-dip thesis.

• Semiconductor capital spending signals: KLAC's October 28 earnings will include forward guidance on wafer fab equipment orders and capital intensity trends for 2027; any commentary on AI infrastructure spending or memory buildouts will move the 895% analyst-target narrative.

• Regional bank deposit flows and net interest margin: AMAL and BANC both report in late October; watch for commentary on deposit betas, loan growth, and credit provisions. Insider selling at both names suggests internal holders expect volatility or slower earnings momentum into year-end.

• Short-squeeze potential in LRN: The 16.4% short interest makes Stride the most crowded short on the screen; any upside earnings surprise or guidance raise on October 27 could trigger a forced cover.

Go Deeper

The value screener surfaces stocks trading at low multiples with strong free cash flow generation, earnings yields above the risk-free rate, and drawdowns that may represent entry points for patient capital.

Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Stock Pixie Pro

See the full Rising Value screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial →

Or start with the free Market Brief Digest

Where the market stands before the open, in plain language, every trading day. No account needed.

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.